12 Best Growth Stocks to Invest In According to Analysts

Page 9 of 11

3. Genmab (NASDAQ:GMAB)

Number of Hedge Fund Holders: 19

Upside Potential as of February 19: 51.39%

Genmab (NASDAQ:GMAB) develops innovative antibody-based therapies for cancer and other serious diseases. With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in oncology and beyond.

Its commercialized medicines, particularly EPKINLY and TIVDAK, are the primary drivers of its revenue. EPKINLY achieved $281 million in sales in 2024, with $78 million in Q4 alone, propelled by strong uptake in the US and Japan. Its potential peak sales are estimated to exceed $3 billion, and three pivotal Phase 3 readouts are expected by the end of 2026. TIVDAK generated $131 million in sales for 2024, with $38 million in Q4, and is recognized as the global standard of care in advanced cervical cancer. Approvals in Japan and Europe are anticipated in 2025.

EPKINLY and TIVDAK account for 34% of the company’s projected revenue growth in 2025, and their sales are a major component of the recurring revenues, which represent 95% of total projected revenue. The commercialized medicines segment as a whole contributed 29% of Genmab’s (NASDAQ:GMAB) revenue growth for 2024.

Page 9 of 11